Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1, OPEN-LABEL, DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF MDV3100 IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

NCT00510718 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00510718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF MDV3100 IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
July 23, 2007
Completion date
April 2, 2018
Enrollment
140 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer, prostate cancer